COVID-19-associated pulmonary aspergillosis: A lesson learned from COVID sequel
Invasive pulmonary aspergillosis (IPA) is now been recognized as a possible secondary infection affecting COVID-19 recovery and increasing mortality. It can be explained due to factors such as direct epithelial injury, hypercoagulable and hyperinflammatory states, and the use of immunosuppressive tr...
Saved in:
| Main Authors: | Priyanka Singh, Aanchal Kakkar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-07-01
|
| Series: | Journal of Current Research in Scientific Medicine |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jcrsm.jcrsm_32_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population pharmacokinetics and dose optimization of voriconazole in patients with COVID-19-associated pulmonary aspergillosis
by: Hui Wang, et al.
Published: (2025-04-01) -
Effect of inflammation on voriconazole levels in patients with invasive pulmonary aspergillosis
by: Pinar Bakir Ekinci, et al.
Published: (2024-10-01) -
COVID-19 Associated Pulmonary Aspergillosis: A Case Series
by: Mira Yulianti, et al.
Published: (2022-07-01) -
Antifungal Treatment for Japanese Patients with Chronic Pulmonary Aspergillosis
by: Takahiro Takazono, et al.
Published: (2024-12-01) -
Observational study of the recent efficacy and economy of itraconazole vs. voriconazole in perioperative pulmonary aspergillosis
by: Peng Chen, et al.
Published: (2025-04-01)